Intussusception following rotavirus vaccination in the Valencia Region, Spain

Silvia Pérez-Vilar1,2,*, Javier Díez-Domingo1,3, Joan Puig-Barberá1, Ruth Gil-Prieto4, and Silvana Romio2,5

1Vaccine Research Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana; FISABIO-Public Health; Valencia, Spain; 2Department of Medical Informatics; Erasmus University Medical Center; Rotterdam, The Netherlands; 3Facultad de Medicina; Universidad Católica de Valencia; 4San Vicente Mártir; Valencia, Spain; 5Area of Preventive Medicine and Public Health; Rey Juan Carlos University; Madrid, Spain; 6Department of Statistics and Quantitative Methods; Division of Biostatistics; Epidemiology and Public Health; Laboratory of Healthcare Research and Pharmacoepidemiology; University of Milano-Bicocca; Milan, Italy

Keywords: intussusception, positive predictive value, rotavirus vaccines, self-controlled case-series (SCCS) method, vaccine safety

Abbreviations: CI, Confidence Interval; CMBD, Spanish hospital discharge database; IRRs, Incidence Rate Ratios; PPV, Positive Predictive Value; RV1, Rotarix® (GlaxoSmithKline Biologicals Rixensart Belgium); RV5, RotaTeq® (Merck & Co. Inc. West Point PA USA); SCCS, Self-Controlled Case Series; SIV, Valencia Vaccine Information System

Manuscript

Two oral live-attenuated rotavirus vaccines are currently available in the global market: a monovalent human vaccine, Rotarix® (GlaxoSmithKline Biologicals, Rixensart, Belgium), indicated as a 2-dose series in infants between the ages of 6–12 and 24 weeks,1 and a pentavalent bovine-human reassortant vaccine, RotaTeq® (Merck & Co., Inc., West Point, PA, USA), indicated as a 3-dose series starting at age 6–12 weeks and ending at age ≤32 weeks.2 Previously, an observed association between Rotashield®, the first licensed rotavirus vaccine, and intussusception, caused its withdrawal from the US market in 1999, only 9 months after licensure.3,4 The pre-licensure clinical trials for both Rotarix® (RV1) and RotaTeq® (RV5), designed to exclude an association with intussusception of similar magnitude than that found for Rotashield®, did not find an association.5,6 However, after licensure, an increased risk, although of much lower magnitude, was found with both vaccines in Australia, Mexico, Brazil, and the United States.7,10

Both vaccines, RV1 and RV5, have been available in Spain since August 2006 and January 2007, respectively. Rotavirus vaccines in Spain are not funded by the National Health System, but are recommended by scientific societies and most pediatricians, and paid for by parents. Due to the incidental finding of circovirus DNA contamination affecting both vaccines, the Spanish Medicines Agency suspended RV5 distribution during June–November 2010, and RV1 distribution since March 2010.11 As of this publication, RV1 remains suspended in Spain.

Intussusception risk varies across population and regions,12 and some studies have shown high background rates of intussusception in Spain;13,14 a potential association with rotavirus vaccination could cause concern. Thus, our aim was to investigate such association in the Valencia Region, Spain.
We performed a hospital-based retrospective observational study during January 1, 2007 – December 31, 2011. Intussusception risk following rotavirus vaccinations was assessed using a self-controlled cases series (SCCS) design. The SCCS is a case-only design that uses individuals who had the event of interest during the study period; we applied the vaccinated cases only SCCS approach, which uses only subjects who were exposed to a rotavirus vaccine. Therefore, inference is done within individuals, and time-fixed confounders are controlled implicitly by design. Unvaccinated individuals and individuals for which vaccination status is unknown are excluded. The observation period (follow-up person-time) for each individual is divided in predefined risk and non-risk periods based on exposure. Therefore, the event of interest falls either into a risk or a non-risk period. In our case, the risk periods were defined as days 1–7, and 8–21, post-vaccination, following each dose of any rotavirus vaccine. The comparison (non-risk) period was days 22–42 following each dose. The study included assessment of the positive predictive value (PPV) of the intussusception code used in the Spanish hospital discharge database, CMBD.

Almost all the Valencia Region population (>98%) is covered by the public health system, and all users have a unique identification number that allows linking all health care databases and all medical records.

Potential intussusception cases among resident infants aged 6–42 weeks, irrespective of their rotavirus vaccination status, were identified from CMBD through the ICD-9-CM code 560.0 in any diagnosis position. A review of hospitalization and primary care medical records of all potential cases was carried out using the standardized Brighton Collaboration case definition for intussusception (see the Table S1 showing the Brighton criteria in the Appendix). First intussusception episodes considered confirmed (Brighton Level 1-Level 2) were included in the analyses. In our study, the event date was the date of onset of symptoms.

The exposure of interest was vaccination with any dose of rotavirus vaccines. Rotavirus vaccination status was obtained from the regional vaccine information system, SIV. Lack of information or inconsistencies were confirmed through phone consultation with parents and verbal verification of the information in the child’s vaccination card.

Dose-specific incidence rate ratios (IRRs), and their 95% confidence intervals (CI), were assessed to investigate the association between confirmed intussusception cases and rotavirus vaccines within the 2 predefined risk periods. The IRR is estimated by within-individual comparisons of the incidence of the event of interest in risk and control periods using person-time denominators. Given the strong confounding effect of age, analyses were adjusted using, as reference, intussusception-hospitalized rates by age in unvaccinated Valencia Region’s children during 2001–2011. Specific rates by age were estimated using data from CMBD and from the Spanish Statistical Office database (www.ine.es); the pattern was modeled using spline function (Fig. 1).

The PPVs were assessed for the different categories of Brighton Collaboration case classification: (1) Level 1, (2) Level 1-Level 2, and (3) Levels 1-Level 2-Level 3. They were stratified for discharge code position and calendar year.

All statistical tests were 2-sided. Statistical significance was defined as p < 0.05. Analyses were performed using Stata/SE 13.1 (StataCorp LP Texas, USA), R 3.0.3 (Foundation for Statistical Computing, Vienna, Austria), SAS 9.2 (SAS Institute, Inc.), and SAS macros developed by Bart Spiessens.

The study was conducted according to the existing legislation including the Good Epidemiological Practices (CIOMS 2009), the Helsinki Declaration (Seoul 2008) and the Law 14/2007, of 3 July, on Biomedical Research, and was approved by the Ethics Research Committee of the Dirección General de Salud Pública/Centro Superior de Investigación en Salud Pública, which provided a waiver to access personal information and contact parents.

The Valencia Region has an annual birth cohort of around 48,000 infants among a total population of approximately 5,000,000 inhabitants. Within the population of interest, infants aged 6 to 42 weeks discharged from hospitals of the Valencia Region’s public health system, 151 potential hospitalized-intussusception cases were identified after having excluded duplicate episodes (children transferred to a reference hospital). Cases occurred in 147 infants, since 4 infants (3%) had a second episode. Medical records were available for all cases. Among first episodes, 125 cases (85.0%) were classified as Level 1, 11 (7.5%) as Level 2, 2 (1.4%) as Level 3, 8 (5.4%) as Insufficient Evidence, and one case (0.7%) was discarded. Of 136 confirmed intussusception cases, 35 (26%) occurred in rotavirus-vaccinated children (Fig. 2). Among them, 14 (40%), and 21 (60%) had received RV1 and RV5, respectively.

The PPV of the diagnosis code for hospitalized intussusception cases (any discharge diagnosis position) was 93% (95% CI: 87%–96%) for Level 1-Level 2 of diagnosis certainty. No differences by discharge diagnosis position or by calendar year were found (Table 1).
Three intussusception cases occurred within days 1–7 following first dose of a rotavirus vaccine (two after RV1 and one after RV5) resulting in a crude IRR point estimate of 9.0 (95% CI: 0.9–86.5), and in an age-adjusted estimate of 4.7 (95% CI:0.3–74.1) within this risk window. The number of cases occurring within 1–7, 8–21, and 22–42 days following each dose, and dose-specific IRRs are shown in Table 2.

In this first post-licensure analytical study of the intussusception risk following rotavirus vaccination in Europe, we investigated intussusception cases among infants discharged from all

![Figure 2. Flowchart of hospitalized-intussusception cases.](image)

### Table 1. Positive predictive values according to The Brighton Collaboration case classification by discharge code position, and by calendar year

| Discharge code position | Cases n | Level 1% (95% CI) | Level 1- Level 2 % (95% CI) | Level 1-Level 2-Level 3 % (95% CI) |
|-------------------------|---------|------------------|-----------------------------|-----------------------------------|
| 1st                     | 148     | 86.5 (79.9–91.5) | 93.2 (87.9–96.7)            | 94.6 (89.6–97.6)                  |
| 1st or 2nd              | 149     | 86.6 (80.0–91.6) | 93.3 (88.0–96.7)            | 94.6 (89.7–97.7)                  |
| Any                     | 151     | 85.4 (78.8–90.6) | 92.7 (87.3–96.3)            | 94.0 (89.0–97.2)                  |
| Calendar year¹          |         |                  |                             |                                   |
| 2007                    | 44      | 81.8 (67.3–91.8) | 90.9 (78.3–97.5)            | 95.5 (84.5–99.4)                  |
| 2008                    | 30      | 86.7 (69.3–96.2) | 93.3 (77.9–99.2)            | 93.3 (77.9–99.2)                  |
| 2009                    | 25      | 84.0 (63.9–95.5) | 92.0 (74.0–99.0)            | 92.0 (74.0–99.0)                  |
| 2010                    | 28      | 89.3 (71.8–97.7) | 92.9 (76.5–99.1)            | 92.9 (76.5–99.1)                  |
| 2011                    | 24      | 87.5 (67.6–97.3) | 95.8 (78.9–99.9)            | 95.8 (78.9–99.9)                  |

¹Any diagnosis position.
Abbreviations: Positive Predictive Value (PPV); Confidence interval (CI).
Table 2. Risk estimates for confirmed intussusception cases after Rotarix®/RotaTeq® vaccination, vaccinees-only SCCS approach

| Vaccine dose | Risk period (days post-vaccination) | Number of cases | Non-risk period (days post-vaccination) | Number of cases | IRR (95% CI) (crude) | IRR (95% CI) (age-adjusted) |
|--------------|-------------------------------------|-----------------|----------------------------------------|-----------------|----------------------|--------------------------|
| Dose 1       | 1–7                                 | 3               | 22–42                                  | 1               | 9.0 (0.9–86.5)       | 4.7 (0.3–74.1)           |
|              | 8–21                                | 1               |                                        |                 | 1.5 (0.1–24.0)       | 0.8 (0.1–13.9)           |
| Dose 2       | 1–7                                 | 1               | 22–42                                  | 2               | 1.5 (0.1–16.5)       | 1.6 (0.1–32.3)           |
|              | 8–21                                | 3               |                                        |                 | 2.3 (0.4–13.5)       | 3.9 (0.3–44.0)           |
| Dose 3       | 1–7                                 | 0               | 22–42                                  | 1               | 3.0 (0.2–48.0)       | Non interpretable1      |
|              | 8–21                                | 0               |                                        |                 | Non interpretable1   | Non interpretable1      |

*The observation period for each vaccine dose ends at day 42 post-vaccination.

1Non-interpretable IRR due to very small numbers.

Abbreviations: Intussusception (IS); Confidence interval (CI).

This study has also shown that a high quality investigation of the safety of childhood vaccinations using Valencian healthcare databases is possible. The high (93%) PPV found for a discharge diagnosis of intussusception has opened the door to the implementation of a larger study without the need to perform medical record reviews. Thus, we plan to continue the study for additional years, and invite also participation from other Spanish regions. Moreover, following verification of the PPV of the discharge diagnosis codes in candidate sites, the study could be extended to include other European databases, thus gaining substantial power for the analysis of this rare event, even if vaccination coverage remains low. Such database integration will substantially improve the capacity for timely post-licensure assessments of the safety of any new vaccines introduced in Europe.

Disclosure of Potential Conflicts of Interest

SPV, JDD, and JPB are working at FISABIO-Public Health, institution that has ongoing research contracts with GlaxoSmithKline Biologicals, Sanofi Pasteur MSD, and Merck & Co., Inc. JDD, JPB and RGP have received support for grants and travel grants from GlaxoSmithKline Biologicals, Sanofi Pasteur MSD, and Merck & Co., Inc. SPV has received travel grants for Scientific Congress from GlaxoSmithKline Biologicals and Sanofi Pasteur MSD. SR has no conflicts of interest.
SR analyzed the data. SPV drafted the manuscript. All authors were involved in interpretation of the results, the critical revision of drafts, and approved the final version of the manuscript.

References

1. Rotarix: Product information. European Medicines Agency, 2009.

2. Rotavac: Product information. European Medicines Agency, 2008

3. Murphy TV, Garzillo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, Zanardi LR, Seria S, Fair E, LeBaron CW, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564-72; PMID:11207352; http://dx.doi.org/10.1056/NEJM200102223440804

4. Kramarz P, France EK, Desterano F, Black SB, Shinefield H, Wierd JL, et al. Population-based study of rotavirus vaccination and intussusception. Pediat Infect Dis J 2001; 20:410-6; PMID:11332666; http://dx.doi.org/10.1097/00006454-200104000-00008

5. Vesikari T, Tousson DO, Demeule P, Van Damme P, Sontosoum M, Rodriguez Z, Dallas MJ, Heyse JF, Coveza MG, Black SB, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33; PMID:16394299; http://dx.doi.org/10.1056/NEJMoa0592664

6. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, et al. Safety and efficacy of an attenuated human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:11-22; PMID:16394298; http://dx.doi.org/10.1056/NEJMoa062544

7. Buttery JP, Danchin MH, Lee KJ, Carlin JB, McIntyre PB, Elliott EJ, Booy R, Bines JE. PAEDS/APSU Study Group. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011; 29:3061-6; PMID:21316503; http://dx.doi.org/10.1016/j.vaccine.2011.01.088

8. Carlin JB, Macartney KK, Lee KJ, Quinn HE, Buttery J, Lopert R, Bines J, McIntyre PB. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia’s National Immunization Program. Clin Infect Dis 2013; 57:1427-34; PMID:23964090; http://dx.doi.org/10.1093/cid/cis520

9. Patel MM, Lopez-Collada VR, Bulhoes MM, De Oliveira LH, Bautista, Marquez A, Flannery B, Esparraga Aguilas M, Montenegro Renreiner EL, Luna-Cruz ME, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011; 364:2283-92; PMID:21675888; http://dx.doi.org/10.1056/NEJMoa11012952

10. Yik WK, Lien TA, Kullendorff M, Martin D, McMahill-Walraven CN, Platt R, Selvan N, Selvan M, Lee GM, Nguyen M. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med 2014; 370:503-13; PMID:24422676

11. Bouzon Alejandro M, Diez Domingo J, Martinon-Torres F. Circovirus and impact of temporary withdrawal of rotavirus vaccines in Spain. Hum Vaccin 2011; 7:798-9; PMID:21715979; http://dx.doi.org/10.4161/hv.7.7.15683

12. Jiang J, Jiang B, Parashar U, Nguyen T, Bines J, Patel MM. Childhood intussusception: a literature review. PLoS One 2013; 8:66848; PMID:23859408; http://dx.doi.org/10.1371/journal.pone.0068482

13. Bines JE, Iannone B. Acute intussusception in infants. Incidence, clinical presentation and management: a global perspective. Vaccines and Biologicals. Geneva: World Health Organization, 2002

14. Bringue Espuny X, Ibarra Valverde Z, Martinez Alonso M, Morales Bara I, Sole Mir E. [Intestinal invagination: change in its incidence from 1987 to 2008]. Cir Pediatr 2010; 23:206-10; PMID:21520551

15. Whittaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006; 25:1768-97; PMID:1620518; http://dx.doi.org/10.1002/sim.2302

16. MacIntyre PB, Fireman B, Nason JC, Hua W, Shouibi A, Paredes A, et al. When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Safety 2012; 21 Suppl 1:50-61; PMID:22262593; http://dx.doi.org/10.1002/pds.2330

17. Ministerio de Sanidad Servicios Sociales e Igualdad. Explotación del registro de alta CMDB del Sistema Nacional de Salud. Spain, 2014.

18. Ministerio de Sanidad Servicios Sociales e Igualdad. Informe Anual del Sistema Nacional de Salud 2011. Spain, 2013.

19. Bines JE, Kohl KS, Forster J, Zanardi LR, Dines RL, Hansen J, et al. Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004; 22:569-74; PMID:14741146; http://dx.doi.org/10.1016/j.vaccine.2003.09.016

20. Pastor-Villalba E, Martín-Ivorra R, Algucal-Ramos AM, Portero-Alonso A, Barberá Catalá MA, Pons Sánchez C, Lluç Rodrigo JA. Sistema de Información Vacunal (SIV). In: Generalitat Valenciana, Conselleria de Sanitat, eds. Valencia (Spain) 2009.

21. Pastor-Villalba E, Martín-Ivorra R, Algucal-Ramos AM, Portero-Alonso A, Lluç Rodrigo J. [Exhaustividad en la declaración en el sistema de información vacunal (SIV) de vacunas no incluidas en el calendario sistemático infantil de la Comunidad Valenciana. Anos 2009 a 2012]. P04. 7th Congress of the Spanish Association of Vaccinology. Càceres (Spain) 2013.

Supplemental Material

Supplemental data for this article can be accessed on the publisher’s website.